The issues is NWBO cherry-picking the healthiest naive GBM patients (fully or nearly complete resection) and comparing the results to external comparator trials that have less health patients. The multiple dosing of DCVas-L (that crossover for 90% of treatment arm) and manipulating the statistics to "compensate" for double dosing when the external comparator trials did not.
It's the biased comparison of the post hoc trial, including the post hoc data dredged rGBM OS arm. It was a NAIVE GBM trial design.
Market Data 
Markets 
AI
